Associations of markers of inflammation and coagulation with delirium during critical illness
- PMID: 22903241
- PMCID: PMC3606929
- DOI: 10.1007/s00134-012-2678-x
Associations of markers of inflammation and coagulation with delirium during critical illness
Abstract
Purpose: To assess the associations between a priori-selected markers of inflammation and coagulation and delirium during critical illness.
Methods: In this prospective cohort study, we collected blood from mechanically ventilated medical intensive care unit (ICU) patients and measured nine plasma markers of inflammation and coagulation. We assessed patients daily for delirium using the Confusion Assessment Method for the ICU and used multivariable regression to analyze the associations between plasma markers and subsequent delirium, after adjusting for age, severity of illness, and sepsis.
Results: Among the 138 patients studied, with median age of 66 years and median Acute Physiology and Chronic Health Evaluation (APACHE) II of 27, 107 (78 %) were delirious at some point during the study. Two markers of inflammation and one of coagulation were significantly associated with delirium. After adjusting for covariates, lower plasma concentrations of matrix metalloproteinase-9 (MMP-9) and protein C were associated with increased probability of delirium (p = 0.04 and 0.01, respectively), and higher concentrations of soluble tumor necrosis factor receptor-1 (sTNFR1) were associated with increased probability of delirium (p < 0.01). Concentrations of C-reactive protein (p = 0.82), myeloperoxidase (p = 0.11), neutrophil gelatinase-associated lipocalin (p = 0.70), D-dimer (p = 0.83), plasminogen activator inhibitor type 1 (p = 0.98), and Von Willebrand factor antigen (p = 0.65) were not associated with delirium.
Conclusions: In this study, MMP-9, protein C, and sTNFR1 were independently associated with subsequent ICU delirium. These results suggest that specific aspects of inflammation and coagulation may play a role in the evolution of delirium during critical illness and that these markers should be examined in larger studies of ICU patients.
Conflict of interest statement
Drs. Girard, Pandharipande, Shintani, and Ely have received honoraria from Hospira Inc. Dr. Pandharipande has received honoraria from Orion Corporation. Drs. Pandharipande and Ely have received grant support from Hospira Inc. Dr. Ely has also received grant support from Eli Lilly and Company and Masimo Corporation and is an advisor to Healthways Inc. All other authors have no disclosures.
Figures
References
-
- Engel GL, Romano J. Delirium, a syndrome of cerebral insufficiency. J Chronic Dis. 1959;9:260–277. - PubMed
-
- Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk factors. Intensive Care Med. 2001;27:1297–1304. - PubMed
-
- Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely EW. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients. Crit Care Med. 2010;38:2311–2318. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL103836/HL/NHLBI NIH HHS/United States
- HL007123/HL/NHLBI NIH HHS/United States
- TL1 RR024978/RR/NCRR NIH HHS/United States
- K24 HL103836/HL/NHLBI NIH HHS/United States
- R01 AG035117/AG/NIA NIH HHS/United States
- AG027472/AG/NIA NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- AG034257/AG/NIA NIH HHS/United States
- K23 AG001023/AG/NIA NIH HHS/United States
- AG001023/AG/NIA NIH HHS/United States
- K23 AG031322/AG/NIA NIH HHS/United States
- KL2 RR024977/RR/NCRR NIH HHS/United States
- K23 AG034257/AG/NIA NIH HHS/United States
- AG031322/AG/NIA NIH HHS/United States
- AG035117/AG/NIA NIH HHS/United States
- R01 AG027472/AG/NIA NIH HHS/United States
- T32 HL007123/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
